Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD
Tag: takeda
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus